Madrigal Pharmaceuticals 3Q 2026: Revenue $431.27M, EPS $1.83— 10-Q Summary
Madrigal Pharmaceuticals reported Q3 2026 revenue of $431.27M, up 50.1% YoY, and net income of $55.44M, reversing a prior-year loss. EPS was $1.83 vs. a loss of $4.01. Rezdiffra revenue grew 74% over nine months, with U.S. demand driving quarterly gains. The company expanded its field force and launched Rezdiffra in Germany.
How this was made
The 30-second read
Why it matters
The combination of a large YoY revenue increase, swing to net income, and specific expansion and trial-start timing can drive near-term sentiment and medium-term expectation setting for MASH therapy adoption and clinical milestones.
Market read
Traders can use the reported quarterly financials and the stated trial and European rollout timelines to update valuation assumptions and catalyst calendars.
What to watch
The summary does not quantify guidance, cash burn, or margin drivers; traders may need the full 10-Q to assess durability of profitability and funding runway.
Background
The piece is a brief summary of Madrigal Pharmaceuticals’ 3Q 2026 10-Q, highlighting financial results and updates on Rezdiffra commercialization and pipeline progression.
Ticker impact
Madrigal reported 3Q 2026 revenue of $431.27M and diluted EPS of $1.83, plus Rezdiffra growth and updated trial timelines.
Likely upward bias as the market prices in accelerating Rezdiffra demand and clearer progression toward MAESTRO-CSPH and future outcomes.
The article provides concrete quarterly financials (revenue, net income, EPS) and specific operational updates (Rezdiffra demand, Germany launch, trial start timing), which are direct inputs to valuation and expectations.
Market effects
Biopharma investors may re-rate GLP-1/MASH-adjacent platforms based on evidence of commercial traction and advancing late-stage trial plans.
Germany launch and planned country-by-country European rollout can influence regional payer and distribution expectations for MASH therapies.
European expansion and multi-program pipeline updates can affect global sentiment toward MASH treatment development timelines.
Counterpoint
Strong quarter and trial plans may already be partially anticipated; investors could focus on sustainability of demand and reimbursement progress in Europe rather than headline growth.
Key entities
- companyMadrigal Pharmaceuticals, Inc.
US-listed biopharmaceutical company reporting 3Q 2026 results and updates on Rezdiffra and its MASH pipeline.
- productRezdiffra
Madrigal’s therapy referenced for revenue growth and European launch timing.
- clinical_trialMAESTRO-CSPH
More than 2,000-patient trial planned to begin in the first half of 2027.
- clinical_trialMAESTRO-NASH
Outcomes data expected in 2028.
